Compare Crispr Therapeutics AG (CRSP) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Suncor Energy Inc. — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Suncor Energy Inc. trades at $61.33 (market cap $71.44B). The key difference: Suncor Energy Inc. is far larger — about 14.4× Crispr Therapeutics AG's market cap, and Suncor Energy Inc. pays a 2.76% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | SU | |
|---|---|---|
Market Cap | $4.97B | $71.44B |
Sector | Health | Energy |
52-Week High | $76.78 | $69.73 |
52-Week Low | $44.34 | $38.17 |
Enterprise Value | $3.32B | $79.57B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Suncor Energy (SU) trades at $61.27, up 3.41% with strong bullish momentum. The stock shows robust fundamentals with a P/E of 16.54, net margin of 11.62%, and consistent dividend payments. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 slightly missed. Technical indicators signal bullish sentiment with the current price near resistance at $62. Analyst consensus is strongly positive with 74% buy ratings.
SU presents a compelling investment case with attractive valuation metrics and strong profitability. However, investors face risks from oil price volatility and recent operational challenges. The company's disciplined capital allocation and record production support long-term value, but macroeconomic headwinds and competitive pressures require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
